Home › Endometrial Cancer › Illinois › Chicago
Endometrial Cancer clinical trials in Chicago, IL
23 studies for Endometrial Cancer are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
RecruitingPhase 1/2
- University of Illinois at Chicago (UIC), Chicago
- University of Chicago, Chicago
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RecruitingPhase 1
- University of Chicago Comprehensive Cancer Center, Chicago
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- and 3 more
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecruitingPhase 2
- Northwestern University, Chicago
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecruitingPhase 3
- University of Chicago Medical Center ( Site 5002), Chicago
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RecruitingObservational study
- University of Chicago, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- University of Illinois Cancer Center, Chicago
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Recruiting
- Northwestern Memorial Hospital, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RecruitingPhase 1
- University of Chicago Medical Center, Chicago
A Study of PHST001 in Advanced Solid Tumors
RecruitingPhase 1
- University of Chicago Medical Center, Chicago
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RecruitingPhase 1/2
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago Medical Center, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Northwestern University Feinberg School of Medicine, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Lurie Children's Hospital-Chicago, Chicago
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RecruitingPhase 2
- Northwestern Medicine, Chicago
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
- University of Chicago Medical Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecruitingPhase 1/2
- Northwestern University, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RecruitingPhase 1/2
- Northwestern Memorial Hospital, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecruitingPhase 1/2
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
RecruitingObservational studyHealthy volunteers welcome
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY54 studies
- Boston, MA51 studies
- Arlington, VA41 studies
- Nashville, TN38 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- Oklahoma City, OK28 studies
- San Antonio, TX27 studies
- Queens, NY26 studies
- Dallas, TX25 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.